It’s got a long way to go. The FDA has found a lot of problems in their screenings to include:
FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes
FDA Drug Safety Communicaion: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate
FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections
FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density
Don’t look for it to be available right away. They have a lot of work to do and it is normal to be years into a study of a drug before it hits the shelves. The C-19 drugs are an example as they were slammed in too quickly as they are finding at the moment.
wy69
I’d say that those potential issues are with people who have serious diabetes. These heart patients may not have those problems.